Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
10531
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Active, not recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 709–720 of 10,531 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

NCT05118854
View directory record Official record
Conditions
Lung Cancer
Interventions
AMG 510, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy

NCT06529029
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder, Schizo Affective Disorder, Bipolar Disorder
Interventions
Sigma-Stim, RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral)
Device · Procedure
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Phase 2 Interventional Results available

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions
Patritumab Deruxtecan (Fixed dose), Patritumab Deruxtecan (Up-Titration)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
33
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

NCT03698019
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Mucosal Melanoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Therapeutic Conventional Surgery
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
815
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 511 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of Matrix Pro for Eyebrow Lift and Lift of Submental/Neck Laxity

NCT06640998
View directory record Official record
Conditions
Laxity; Skin
Interventions
Matrix Pro
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The PorchLight Project

NCT05550727
View directory record Official record
Conditions
Memory Loss, Alzheimer Disease, Dementia
Interventions
PorchLight
Other
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Phase 2 Interventional

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)

NCT06111586
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Frexalimab, Placebo, Insulin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 35 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
14
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Not applicable Interventional Results available

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

NCT02701283
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
2,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
61
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Not applicable Interventional

Napoleon Measurement of Gastrojejunal Anastomosis

NCT04832282
View directory record Official record
Conditions
Gastric Bypass, Weight Regain
Interventions
Napoleon, Visual estimation
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Phase 3 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

NCT01575548
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
579
States / cities
Fairbanks, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 355 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Petosemtamab, Pembrolizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
36
States / cities
Mobile, Alabama • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST
Active, not recruiting Not applicable Interventional

Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer

NCT01794403
View directory record Official record
Conditions
Prostate Cancer
Interventions
Extended Hypofractionation Radiotherapy, Accelerated Hypofractionation Radiotherapy
Radiation
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 11, 2026, 3:05 AM EST